Peptides for Stomach Issues: What the Evidence Shows on Digestive Support

Key Takeaways

• Compounds covered: BPC-157, KPV (Lys-Pro-Val), larazotide acetate
• Goal area: Gastric and intestinal symptom support — nausea, bloating, ulcer healing, mucosal protection, intestinal permeability
• Evidence range: Ranges from extensive preclinical animal models (BPC-157) to limited gut-specific animal data (KPV) to early human intestinal permeability trials (larazotide)
• Regulatory range: BPC-157 and KPV are not on the FDA 503A Category 1 list, have no USP monograph, and are not components of any FDA-approved drug — neither is lawfully compoundable under Section 503A; both sit on the Category 2 interim list. Larazotide acetate is an investigational new drug under an active IND, not FDA-approved, and not lawfully compoundable under 503A. None are FDA-approved for GI indications.
• Key biomarkers for gut health: hs-CRP (systemic inflammation), ALT/AST (liver safety baseline), eGFR (kidney function), comprehensive metabolic panel
• As of April 21, 2026: BPC-157 is on the FDA Category 2 interim bulk-substance list with a PCAC proposal pending; Category 2 is interim administrative, and removal would not by itself make BPC-157 compoundable under 503A. No peptide discussed in this article is FDA-approved for any gastrointestinal indication.
• Bottom line: Preclinical evidence for BPC-157 in GI applications is extensive in animals; human trial data is almost entirely absent, making clinical conclusions premature. This article is educational and is not intended to diagnose or treat any GI condition.

Stomach issues span a wide biological territory: gastric ulcers driven by acid and mucosal breakdown, reflux from sphincter dysfunction, inflammatory conditions of the small intestine, and the poorly defined category of functional GI symptoms including bloating, nausea, and abdominal discomfort after meals. The mechanisms underlying these conditions differ substantially. Any compound proposed to address multiple of them would need to operate across several biological systems simultaneously.

That is precisely the proposed profile of BPC-157, which has an extensive preclinical GI evidence base. Understanding what that evidence actually shows — and where its limits are — is the organizing task of this article.

Understanding Stomach and GI Health: The Biology

The gastrointestinal tract is protected from its own digestive chemistry by a mucosal defense system. The gastric mucosa secretes a bicarbonate-rich mucus layer that physically separates the epithelial lining from hydrochloric acid and pepsin. Prostaglandins, particularly PGE2, reinforce this defense by stimulating mucus and bicarbonate secretion and maintaining mucosal blood flow. When this defense is disrupted — by NSAID use (which inhibits prostaglandin synthesis), H. pylori infection, bile reflux, or chronic acid overproduction — the result is mucosal injury ranging from superficial erosions to full-thickness ulcers.

The lower esophageal sphincter (LES) governs the boundary between the stomach and esophagus. When LES pressure falls or sphincter coordination is disrupted, acid reflux occurs, producing esophageal injury over time. The pyloric sphincter controls gastric emptying; dysfunction in either sphincter produces characteristic symptom patterns including reflux, bloating, and distension.

At the intestinal level, tight junction proteins — occludin, claudins, and zonulin-regulated components — maintain epithelial barrier integrity. Barrier disruption allows luminal contents to pass into the submucosa, activating inflammatory cascades. Fasano's 2011 review in Physiological Reviews established zonulin as a physiological regulator of intestinal tight junction permeability, and identified increased permeability as a contributor to systemic inflammatory signaling. This pathway is relevant to peptides studied for their tight junction-stabilizing or anti-inflammatory effects.

The gut-brain axis adds a further layer: serotonin and dopamine signaling in the enteric nervous system modulates both gut motility and gut-brain communication. Dysregulation of this axis contributes to functional GI symptoms including nausea, cramping, and bloating — symptoms that are not purely structural but involve neurotransmitter-mediated motility changes.

Peptides Studied for Stomach Issues: A Quick Comparison

The following peptides have published evidence relevant to GI symptom biology. They are listed by the weight of that evidence, from most-studied to least. All three are either preclinical or early-stage; none has completed a Phase 3 human trial for any GI indication.

• Compound: BPC-157
  Mechanism for stomach health: Cytoprotection via nitric oxide system modulation; VEGF-driven angiogenesis supporting mucosal repair; sphincter pressure normalization; gut-brain axis modulation via serotonin and dopamine systems
  Evidence: Extensive animal studies (multiple organ systems, multiple injury models); one published human IV safety pilot (2025, N=small); no completed human efficacy RCT
  FDA status: Not FDA-approved for any indication. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A. Currently on the Category 2 interim list with a PCAC proposal pending
  SP availability: Not available through Superpower
  Route: Subcutaneous or intramuscular injection in animal studies; oral administration also studied in animals
• Compound: KPV (Lys-Pro-Val)
  Mechanism for stomach health: MC3R agonism; NF-κB pathway suppression; anti-inflammatory signaling in intestinal epithelial cells in animal models; uptake via PepT1 oligopeptide transporter
  Evidence: Animal colitis models; in vitro intestinal cell studies; no completed human clinical trials
  FDA status: Not FDA-approved under 21 U.S.C. § 355. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A and not lawfully prescribable as a finished drug product in the US
  SP availability: Not available through Superpower
  Route: Oral or local delivery studied in animals
• Compound: Larazotide acetate
  Mechanism for stomach health: Proposed tight junction assembly promotion; studied for effects on intestinal permeability via stabilization of epithelial barrier proteins
  Evidence: Phase 2 human trials in celiac disease (intestinal permeability endpoints); not studied for general stomach symptoms
  FDA status: Investigational new drug under an active IND; not FDA-approved. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A
  SP availability: Not available through Superpower
  Route: Oral capsule (studied in clinical trials)

Compounds described here as not lawfully prescribable in the US are compounds that (i) have not received FDA approval as new drugs under 21 U.S.C. § 355, (ii) are not on the FDA 503A Category 1 list of bulk drug substances permitted for compounding, (iii) do not have an applicable USP monograph, and (iv) are not components of any FDA-approved drug — meaning there is no statutory pathway for a US pharmacy to compound or a US prescriber to prescribe them as finished drug products. Their inclusion here is for educational context only.

Peptides Studied for Stomach Issues: Individual Profiles

Each compound works through a distinct mechanism and has a distinct evidence record. Direct comparison requires acknowledging that they have been studied in different injury models, at different doses, and with different endpoints.

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide (Body Protection Compound 157) derived from a sequence in human gastric juice, studied primarily in animal models across the full GI tract from esophagus to intestine. It is not FDA-approved for any indication and is not an approved drug in any regulatory market.

For gastric protection, the proposed mechanism involves cytoprotection via nitric oxide (NO) system activation, direct mucosal stabilization, and angiogenesis through VEGFR2 upregulation. Sikiric and colleagues, writing in Current Pharmaceutical Design in 2011, reviewed BPC-157 as a proposed GI therapeutic, covering gastric ulcer, esophagitis, duodenal injury, and intestinal protection across multiple experimental models. In a 2004 study in the World Journal of Gastroenterology, Sikiric and colleagues reported dose-dependent ulcer area reduction in rats. The same research group, in a 2010 paper in Current Pharmaceutical Design, proposed that BPC-157 fits within the classical cytoprotection framework originally described by Robert. For NSAID-related gastric injury, Chang and colleagues published evidence in 2020 in Current Pharmaceutical Design on BPC-157 and NSAID-induced intestinal injury in rodent models. The NO-mediated mechanism was further characterized in a 2008 paper by Sikiric and colleagues in the Journal of Pharmacological Sciences, which BPC-157's fistula healing and NO system, with relevance for mucosal blood flow regulation. For reflux and esophageal injury, a 1999 study in the Journal of Physiology (Paris) reported that BPC-157 produced cytoprotection compared with ranitidine and sucralfate in a rat reflux esophagitis model. Dobric and colleagues, in a 2007 Journal of Pharmacological Sciences rat study, BPC-157 and esophagitis in rats, consistent with subsequent work on BPC-157 and lower esophageal sphincter pressure in rodent models. For intestinal permeability, Hsieh and colleagues in a 2017 paper in the Journal of Molecular Medicine BPC-157's pro-angiogenic activity via VEGFR2, providing a vascular mechanism for how the peptide repairs damaged mucosal tissue. Sikiric and colleagues published a 2023 paper in Pharmaceuticals documenting BPC-157 and brain-gut axis recovery, relevant to the neurological component of functional GI symptoms. A comprehensive 2025 review by Jozwiak and colleagues in Pharmaceuticals BPC-157 multifunctional mechanisms review across organ systems, representing the most current evidence narrative.

The critical limitation: a small 2025 pilot safety study published in Alternative Therapies in Health and Medicine provided preliminary pharmacokinetic and acute tolerability data on IV BPC-157 in a small human sample; pilot pharmacokinetic work is not equivalent to adequate and well-controlled efficacy trials under 21 CFR 314.126 and does not establish GI safety or efficacy. No completed human RCT for any GI indication exists.

[Animal study evidence only for GI applications — no completed human efficacy RCTs]

As of April 21, 2026, BPC-157 is not on the FDA 503A Category 1 list, does not have a USP monograph, and is not a component of any FDA-approved drug — so it does not qualify for lawful 503A compounding under 21 U.S.C. § 353a(b)(1)(A). It currently sits on the Category 2 interim list with a PCAC proposal pending; Category 2 is interim administrative, and removal would not by itself make BPC-157 compoundable under 503A. Not available through Superpower.

KPV (Lys-Pro-Val)

KPV is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), consisting of three amino acids: lysine, proline, and valine. It is not FDA-approved under 21 U.S.C. § 355, is not on the FDA 503A Category 1 list, has no USP monograph, and is not a component of any FDA-approved drug — so it is not lawfully compoundable under Section 503A or lawfully dispensable as a finished drug product in the US. Its inclusion here is for educational context only.

The proposed mechanism for gut applications involves KPV's uptake by intestinal epithelial cells via the PepT1 oligopeptide transporter, after which it activates melanocortin receptor 3 (MC3R) to suppress NF-κB-driven inflammatory signaling. Dalmasso and colleagues, writing in Gastroenterology in 2008, reported that KPV reduced intestinal inflammation via PepT1-mediated transport in an in vitro and animal colitis model. Sun and colleagues, writing in ACS Biomaterials Science and Engineering in 2021, reported KPV effects in a nanoparticle-delivered colitis model in animals. Land, writing in the International Journal of Physiology, Pathophysiology and Pharmacology in 2012, melanocortin peptides and MC3R anti-inflammatory mechanisms, providing the broader mechanistic rationale cited in the KPV literature for MC3R-mediated NF-κB suppression.

[Animal studies and in vitro data only — no human clinical trial data]

Not FDA-approved for any indication. Not lawfully compoundable or prescribable in the US as a finished drug product. Not available through Superpower or any licensed prescriber for this use.

Larazotide acetate

Larazotide acetate is a synthetic octapeptide studied as a tight junction regulator through promotion of tight junction assembly and opposition to zonulin effects on intestinal barrier permeability. Unlike BPC-157 and KPV, it is an investigational new drug under an active IND program that has completed Phase 2 human trials in celiac disease — making it the most clinically advanced compound discussed here for intestinal permeability applications.

Kelly and colleagues, writing in Alimentary Pharmacology & Therapeutics in 2013, reported that larazotide acetate modulated tight junction permeability in a Phase 2 randomized placebo-controlled trial of patients with coeliac disease undergoing gluten challenge. Its evidence base is specific to celiac disease and zonulin-mediated permeability — not general gastric symptoms such as nausea or bloating.

[Phase 2 human data in celiac disease specifically — not general stomach symptoms]

Larazotide acetate is an investigational new drug under an active IND program. It is not FDA-approved as a finished drug, is not on the FDA 503A Category 1 list, does not have a USP monograph, and is not a component of any FDA-approved drug — so it is not lawfully compoundable under Section 503A. Access for patients is limited to enrollment in an active clinical trial under the sponsor's IND, or — if offered by the sponsor — expanded access under 21 CFR 312.300. Patients interested in larazotide should consult ClinicalTrials.gov (search: larazotide) for current trial enrollment status. Not available through Superpower.

Regulatory Status at a Glance

As of April 21, 2026, the peptides discussed in this article carry the following regulatory statuses:

• BPC-157: Not FDA-approved for any indication. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A. Currently on the Category 2 interim list with a PCAC proposal pending. Category 2 removal, if it occurs, would not by itself make BPC-157 compoundable under 503A.
• KPV (Lys-Pro-Val): Not FDA-approved under 21 U.S.C. § 355. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A or lawfully dispensable as a finished drug product in the US.
• Larazotide acetate: Investigational new drug under an active IND program. Not FDA-approved, not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A. Access is limited to clinical trial enrollment under the sponsor's IND.

Online sellers distributing BPC-157 or KPV for human use are distributing unapproved new drugs in interstate commerce in violation of 21 U.S.C. § 355(a). "Research Use Only" labeling by sellers does not cure this where intended use for human consumption is evident (21 CFR 201.128 intended use doctrine). These products have not been evaluated by FDA for identity, purity, strength, safety, or efficacy. Their presence in this article is for educational context only.

Considerations When Comparing Peptides for Stomach Issues

Direct comparison between these compounds is not straightforward. They have been studied in different GI injury models, at different doses, and using different endpoints. Inferring relative effectiveness from separate preclinical studies in different animal models is methodologically unreliable.

Your specific GI symptom pattern: The three compounds target different aspects of GI biology. BPC-157's evidence spans from esophagus through intestine with particular depth in ulcer and sphincter models. KPV's evidence is concentrated in inflammatory bowel pathology. Larazotide's evidence is specific to intestinal permeability in celiac disease. A symptom presentation involving reflux, nausea, or bloating maps differently onto these profiles than one involving intestinal inflammation.

Existing diagnosis and clinical evaluation: Persistent GI symptoms require clinical evaluation before any intervention is considered. A primary care workup or gastroenterology referral should precede any discussion of these compounds. Note that the peptides discussed in this article are not lawfully prescribable in the US for GI indications; clinical evaluation may identify evidence-based approaches including FDA-approved prescription medications with established safety profiles for the specific condition. Without a diagnosis, the mechanistic relevance of any specific peptide is unclear.

Evidence level: The three compounds in this article have different evidence weights. BPC-157 has the most extensive preclinical record — but preclinical records do not reliably predict human efficacy, as documented across numerous drug development programs. KPV has a more focused but thinner preclinical record. Larazotide has human trial data, but specifically in celiac disease. A provider will evaluate these distinctions carefully.

Regulatory status and access: As of April 21, 2026, none of the compounds in this article are lawfully prescribable or compoundable in the United States for GI applications. BPC-157 is not on the FDA 503A Category 1 list, has no USP monograph, and is not a component of any approved drug; it currently sits on the Category 2 interim bulk-substance list with a PCAC proposal pending. KPV and larazotide acetate are also not on Category 1, and larazotide is an active IND under pharmaceutical development. None qualifies for 503A compounding. Any product sold online claiming to be BPC-157 or KPV is an unapproved new drug in interstate commerce. This is not a minor consideration.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

No blanket safety statement applies across these compounds. Their safety profiles in humans are largely uncharacterized — not because they have been studied and found safe, but because adequate human safety data does not exist for GI applications.

For BPC-157 specifically, a 2025 pilot IV BPC-157 study provided preliminary pharmacokinetic and acute tolerability data in a small human sample. Pilot pharmacokinetic work is not equivalent to adequate and well-controlled efficacy trials under 21 CFR 314.126 and does not establish GI safety or efficacy. Animal toxicology studies have not identified organ toxicity at typical study doses. However, the absence of evidence of harm in short-term animal studies and a small human pharmacokinetic study is not the same as an established safety profile.

Online sellers distributing BPC-157 or KPV for human use are distributing unapproved new drugs in interstate commerce in violation of 21 U.S.C. § 355(a). "Research Use Only" labeling by sellers does not cure this violation where intended use for human consumption is evident (21 CFR 201.128, intended use doctrine). Products have not been evaluated by FDA for identity, purity, strength, safety, or efficacy. Contamination, dosing inconsistency, and misidentification of the compound itself are documented risks across the unregulated injectable category.

Contraindications that apply broadly to this category:

• Active or suspected GI malignancy — any compound with tissue-stimulating or angiogenic properties carries theoretical concern in malignant tissue; none of these compounds have been studied in this population
• Pregnancy or breastfeeding — reproductive and developmental safety data does not exist for any compound in this article
• Current use of prescription medications for GI conditions — potential interactions have not been characterized in humans
• Sourcing from unregulated online vendors — products sold outside licensed pharmacy channels carry contamination and dosing risks that cannot be mitigated by the end user

For compound-specific side effect profiles, consult the individual compound literature and a qualified healthcare provider.

What to Test Before Starting Peptides for Stomach Issues

Regardless of which compound you and your provider discuss, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether a compound is producing the expected physiological changes — or whether those changes are beneficial. For GI applications specifically, inflammatory markers and liver and kidney function baselines are the most directly relevant.

• hs-CRP (high-sensitivity C-reactive protein): Measures systemic inflammatory burden. Why it matters for stomach health: many GI conditions are accompanied by elevated systemic inflammation, and hs-CRP provides an objective reference point for tracking inflammatory changes over time. A baseline value is essential for interpreting any subsequent change.
• ALT (alanine aminotransferase): Measures hepatocellular stress. Why it matters: any injectable compound is processed through the liver, and a pre-treatment ALT baseline identifies pre-existing liver enzyme elevation that would confound interpretation of any subsequent changes.
• AST (aspartate aminotransferase): A second liver enzyme marker. Why it matters: ALT and AST together provide a more complete hepatic safety baseline. An AST baseline is standard pre-treatment assessment for any compound with hepatic metabolism.
• eGFR (estimated glomerular filtration rate): Measures kidney filtration function. Why it matters: renal clearance affects the pharmacokinetics of injectable peptides, and impaired kidney function alters how any compound is processed. A pre-treatment eGFR value is part of standard injectable compound safety assessment.
• Comprehensive metabolic panel: Covers liver enzymes, kidney function, electrolytes, and glucose in a single panel. Why it matters: provides the full organ-function baseline relevant to any injectable compound or significant dietary intervention.
• CBC (complete blood count): Provides context for immune and inflammatory activity. Elevated white blood cell counts or other CBC abnormalities can indicate underlying inflammatory or infectious causes of GI symptoms that should be evaluated clinically before any compound is considered.

These markers establish the objective baselines that make any biological change during any intervention interpretable. Persistent GI symptoms that have not been clinically evaluated warrant a gastroenterology referral — baseline bloodwork supports that clinical conversation regardless of which direction it leads.

How to Access These Peptides Safely

As of April 21, 2026, none of the compounds in this article are lawfully prescribable or compoundable in the United States for GI applications. BPC-157 is not on the FDA 503A Category 1 list, has no USP monograph, and is not a component of any approved drug; it currently sits on the Category 2 interim bulk-substance list, with a PCAC proposal pending. KPV and larazotide acetate are also not on Category 1, and larazotide is an active IND under pharmaceutical development. None qualifies for 503A compounding. This is the current regulatory reality, and it affects the question of access directly.

For anyone experiencing persistent GI symptoms, the appropriate access pathway is clinical: a primary care physician or gastroenterologist can evaluate the symptom pattern, order relevant diagnostics, and identify evidence-based approaches for the specific condition. That evaluation may include prescription medications with established safety profiles — proton pump inhibitors for acid-related injury, immunosuppressants for inflammatory bowel disease, or other approved therapies depending on the diagnosis.

Products marketed online as BPC-157, KPV, or other "gut health peptides" are not subject to FDA manufacturing oversight. Independent testing of such products has found contamination, incorrect dosing, and misidentified compounds. A clinical evaluation before considering any compound in this category is not a bureaucratic formality — it is the mechanism by which the appropriate intervention for your specific biology gets identified.

Understanding Your Baseline

With multiple compounds proposed for stomach issues — each operating through different mechanisms, each with a different evidence profile — the most durable starting point is not a compound selection but a biological baseline. Knowing your inflammatory marker levels, liver function, and kidney function before any intervention gives the data that makes subsequent changes interpretable. Without that reference point, any change observed is uninterpretable.

That principle — test first, then decide — is central to Superpower's data-first approach to health. Whether the clinical conversation that follows leads to an evidence-based prescription, a lifestyle-first approach, or further diagnostic workup, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

BPC-157 is not approved by the FDA for any medical use. Research on BPC-157 has been limited primarily to laboratory and animal studies, with minimal human clinical trial data. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established for gastrointestinal or any other indication. As of April 21, 2026, BPC-157 is not on the FDA 503A Category 1 list, has no USP monograph, and is not a component of any FDA-approved drug — it does not qualify for lawful 503A compounding. It currently sits on the Category 2 interim list with a PCAC proposal pending; Category 2 removal, if it occurs, would not by itself make BPC-157 compoundable under 503A. BPC-157 is not prescribed, compounded, or dispensed through Superpower, and there is no lawful pathway for any US pharmacy to compound or any US prescriber to prescribe BPC-157 as a finished drug product under current FDA rules. This page is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

KPV (Lys-Pro-Val) is not approved by the FDA for any medical use. Research is limited to laboratory and animal studies. Safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. KPV is not FDA-approved as a drug under 21 U.S.C. § 355, is not on the FDA 503A Category 1 list, has no applicable USP monograph, and is not a component of any FDA-approved drug — so it cannot be lawfully compounded under Section 503A or lawfully dispensed as a finished drug product in the US. KPV is not prescribed, compounded, or dispensed through Superpower. Inclusion in this article is for educational purposes only.

Larazotide acetate is an investigational new drug under an active IND program. It is not FDA-approved as a finished drug, is not on the FDA 503A Category 1 bulk-substance list, does not have a USP monograph, and is not a component of any FDA-approved drug. It is therefore not lawfully compoundable under Section 503A. Access for patients is limited to enrollment in an active clinical trial under the sponsor's IND, or — if offered by the sponsor — expanded access under 21 CFR 312.300. Patients interested in larazotide should consult ClinicalTrials.gov (search: larazotide) for current trial enrollment status. Larazotide acetate is not prescribed, compounded, or dispensed through Superpower.

This content is not a substitute for medical advice, diagnosis, or treatment. Persistent gastrointestinal symptoms require clinical evaluation by a licensed healthcare provider. Individual health conditions, medications, and organ function affect both suitability and response to any compound.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.